Senti Biosciences Holdings, Inc.
A biotech company that builds cells engineered with "gene circuits" — biological software programmed in so the cells can sense, compute, and respond much like a computer. Its therapies target hard-to-treat cancers, and the engineered cells are designed to attack tumors while sparing healthy tissue. Founded in 2016 by synthetic-biology pioneers, the name "Senti" comes from the cells' ability to "sense" their environment.
Granted 948.4K · Sold 4.5K
Granted 131.0K
Granted 112.5K
Granted 179.4K · Sold 1.5K
Granted 5.75M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Celadon Partners SPV 2410% owner · 1 transaction | — | 9.78Mas of Mar 2025 | — | — | — |
| Bayer Aktiengesellschaft +3 co-filers10% owner · 1 transaction | — | 2.81Mas of Mar 2025 | — | — | — |
| Lu Timothy KCEO, Director · 6 transactions | — | 745.3K | 948.4K | — | 4.5K |
| Baskett Forest +6 co-filers10% owner · 1 transaction | — | 442.6Kas of Mar 2025 | — | — | — |
| Knobelman DeborahChief Financial Officer, Head of Corporate Development · 2 transactions | — | 131.0Kas of Feb 2024 | 131.0K | — | — |
| Epstein David RDirector · 1 transaction | — | 123.3Kas of Jun 2022 | 112.5K | — | — |
| Rajangam KanyaPres. & Chief Med. & Dev. Off. · 7 transactions | — | 107.8K | 179.4K | — | 1.5K |
| Dynamics Sponsor LLCDirector, 10% owner · 2 transactions | — | 0as of Jun 2022 | 5.75M | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -5.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.